OSELTAMIVIR PHOSPHATE - Generic Drug Details

What are the generic sources for oseltamivir phosphate and what is the scope of patent protection?

Oseltamivir phosphate is the generic ingredient in two branded drugs marketed by Accord Hlthcare, Alembic, Amneal Pharms, Beijing Jialin, Cediprof Inc, Epic Pharma Llc, Hetero Labs Ltd Iii, Invagen Pharms, Laurus, Lupin, Macleods Pharms Ltd, MSN, Natco, Rising, Shandong, Strides Pharma, Sunshine, Upsher Smith Labs, Zhejiang Poly Pharm, Zydus Pharms, Roche, Ajanta Pharma Ltd, Alvogen, Amneal Pharms Ny, Aurobindo Pharma Ltd, Hetero Labs Ltd V, Jubilant Generics, Leading, Pharmobedient, and Teva Pharms Usa, and is included in thirty-eight NDAs. Additional information is available in the individual branded drug profile pages.

There are eight drug master file entries for oseltamivir phosphate. Thirty-six suppliers are listed for this compound.

Summary for OSELTAMIVIR PHOSPHATE

US Patents:	0
Tradenames:	2
Applicants:	30
NDAs:	38
Drug Master File Entries:	8
Finished Product Suppliers / Packagers:	36
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	27
Patent Applications:	7,553
What excipients (inactive ingredients) are in OSELTAMIVIR PHOSPHATE?	OSELTAMIVIR PHOSPHATE excipients list
DailyMed Link:	OSELTAMIVIR PHOSPHATE at DailyMed

Recent Clinical Trials for OSELTAMIVIR PHOSPHATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Nanjing Zenshine Pharmaceuticals	PHASE3
Nanjing Zenshine Pharmaceuticals	Phase 1
Laboratorios Andromaco S.A.	Phase 1

See all OSELTAMIVIR PHOSPHATE clinical trials

Pharmacology for OSELTAMIVIR PHOSPHATE

Drug Class	Neuraminidase Inhibitor
Mechanism of Action	Neuraminidase Inhibitors

Medical Subject Heading (MeSH) Categories for OSELTAMIVIR PHOSPHATE

Antiviral Agents

Enzyme Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for OSELTAMIVIR PHOSPHATE

J05AH	Neuraminidase inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for OSELTAMIVIR PHOSPHATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAMIFLU	for Oral Suspension	oseltamivir phosphate	6 mg/mL	021246	1	2015-06-18
TAMIFLU	Capsules	oseltamivir phosphate	30 mg and 45 mg	021087	1	2011-08-02
TAMIFLU	Capsules	oseltamivir phosphate	75 mg	021087	1	2010-11-15

US Patents and Regulatory Information for OSELTAMIVIR PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Strides Pharma	OSELTAMIVIR PHOSPHATE	oseltamivir phosphate	CAPSULE;ORAL	209421-001	Jun 8, 2018	AB	RX	No	No
Invagen Pharms	OSELTAMIVIR PHOSPHATE	oseltamivir phosphate	CAPSULE;ORAL	217467-001	Oct 3, 2023	AB	RX	No	No
Zydus Pharms	OSELTAMIVIR PHOSPHATE	oseltamivir phosphate	CAPSULE;ORAL	208578-002	Feb 24, 2017	AB	RX	No	No

Expired US Patents for OSELTAMIVIR PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Roche	TAMIFLU	oseltamivir phosphate	FOR SUSPENSION;ORAL	021246-002	Mar 21, 2011	5,952,375*PED
Roche	TAMIFLU	oseltamivir phosphate	CAPSULE;ORAL	021087-003	Jul 2, 2007	5,763,483*PED
Roche	TAMIFLU	oseltamivir phosphate	FOR SUSPENSION;ORAL	021246-002	Mar 21, 2011	5,763,483*PED

Market Dynamics and Financial Trajectory for Oseltamivir Phosphate

Last updated: March 19, 2026

What is the current market landscape for Oseltamivir Phosphate?

Oseltamivir phosphate, marketed under brand names such as Tamiflu, remains a widely used antiviral medication for the treatment and prevention of influenza. The drug's global market experienced significant shifts during the COVID-19 pandemic, affecting demand and supply dynamics.

Market Size and Growth Trends

As of 2022, the global antiviral drugs market was valued at approximately $46 billion, with oseltamivir representing a substantial portion, estimated at around $4 billion in sales. The compound annual growth rate (CAGR) from 2018 to 2022 was about 3.2%. Growth rates have been influenced by factors including seasonal influenza outbreaks, pandemic preparedness, and healthcare policies.

Key Market Players and Production

Major manufacturers include Roche (original patent holder), Glenmark Pharmaceuticals, and Mylan. Roche's Tamiflu retains patent exclusivity in several countries until 2023; following patent expirations, generic production by other firms has increased.

Regulatory Environment

The patent expiration in key markets, such as the US (patented until 2023), has opened pathways for generic manufacturers, increasing market competition and reducing prices. Regulatory agencies continue to monitor usage guidelines, especially in light of the COVID pandemic, where off-label use and stockpiling increased demand.

How has the COVID-19 pandemic affected Oseltamivir's market?

The pandemic initially restricted the use of influenza antivirals, focusing healthcare resources on COVID-19. Nonetheless, the demand for Oseltamivir persisted due to its role in managing seasonal flu, with stockpiling behaviors observed globally. Supply chain disruptions during early pandemic phases limited availability in some regions, but manufacturing capacity was augmented subsequently.

Impact on Demand and Supply

During 2020-2021, demand declined temporarily but rebounded in subsequent flu seasons, driven by in-person activity and delayed vaccinations. The pandemic also spurred research into repurposing existing antivirals, though Oseltamivir's role remained primarily in influenza treatment.

What are the factors influencing the financial trajectory?

Multiple factors influence the revenue outlook for Oseltamivir phosphate:

• Patent status and generics: Patent expiration in 2023 in multiple jurisdictions significantly increases generic availability, intensifying price competition.
• Seasonal influenza trends: Variations in yearly flu incidence impact demand. Mild flu seasons reduce prescriptions; severe ones increase them.
• Healthcare policies: Governments stockpile antivirals, influence procurement policies, and implement vaccination campaigns, which in turn modulate demand.
• Emergence of alternative treatments: New antivirals or combination therapies may supplant Oseltamivir in some markets, affecting future sales.
• Geographic expansion: Markets in developing countries with increasing healthcare access expand the potential customer base.

Price Dynamics

Pre-patent expiration, Tamiflu was priced between $60 and $80 per treatment course. Post-generic entry, average prices dropped below $30 per course in several markets. Price elasticity varies regionally, influenced by healthcare provider practices and insurance reimbursement policies.

Revenue Forecasts

Projection models suggest that global Oseltamivir revenues could decline at an average CAGR of 4-5% over the next five years, driven by generic competition. However, during peak flu seasons, sales temporarily spike by as much as 15-20%.

How does Oseltamivir compare with emerging treatments?

Newer antivirals like Baloxavir marboxil (Xofluza) offer single-dose regimens with rapid onset of action. While market share shifts towards these agents, Oseltamivir maintains a critical role due to established safety profiles, familiarity, and cost factors.

Conclusion

Oseltamivir phosphate remains a significant antiviral drug with fluctuating revenues aligned to seasonal influenza patterns, patent status, and the pandemic context. The upcoming entry of generics in several markets will pressure prices and profit margins but may expand adoption in emerging markets.

Key Takeaways

• The global market for Oseltamivir was worth approximately $4 billion in 2022.
• Patent expiry in 2023 leads to increased generic competition, reducing prices.
• Demand is seasonal and influenced by influenza severity, healthcare policies, and pandemic impacts.
• Revenue is projected to decline annually by 4-5% over the next five years due to generics.
• Competition from newer antiviral agents persists, potentially altering market dynamics.

FAQs

1. When does the patent for Oseltamivir in key markets expire?
Patent expiration is expected in the United States and Europe in 2023, facilitating generic production.

2. How has the COVID-19 pandemic influenced Oseltamivir sales?
Demand temporarily declined during early pandemic phases but rebounded as seasonal flu patterns resumed and stockpiling increased.

3. What are the main factors affecting Oseltamivir’s price?
Patent status, generic competition, regional healthcare policies, and flu severity influence pricing trajectories.

4. Are there alternatives to Oseltamivir with better efficacy?
Yes, such as Baloxavir marboxil, which offers a single-dose regimen with faster symptom relief.

5. What regions hold the largest growth potential for Oseltamivir?
Emerging markets with expanding healthcare infrastructure and increasing influenza awareness are key growth areas.

---

References

[1] MarketWatch. (2022). Global Antiviral Drugs Market Size, Share & Trends Analysis Report.
[2] European Medicines Agency. (2022). Summary of Product Characteristics for Tamiflu.
[3] IQVIA. (2022). Global Life Sciences Data, Reports & Intelligence.
[4] World Health Organization. (2022). Influenza Update – Annual Summary.
[5] FDA. (2022). Patent Expiry Dates and Generic Entry for Oseltamivir.